Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs TWI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TWI's multiple
Needs TWI P/E.
Implied fair value · at HRMY's multiple
Needs EPS (TTM) is negative, HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · TWI FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
TITAN INTERNATIONAL, INC. · implied price per share
Bear
-$3.41
Base
-$4.01
Bull
-$4.61
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
1.24x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
3.75x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$231.88M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
NUCOR CORP
HRMY vs NUE
STEEL DYNAMICS INC
HRMY vs STLD
UNITED STATES STEEL CORP
HRMY vs X
KAISER ALUMINUM CORP
HRMY vs KALU
RELIANCE, INC.
HRMY vs RS
$163.66M
$639.76M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY should be valued on its own stronger profitability and growth profile rather than on TWI's weak comp multiple, then maintain a constructive view on HRMY because its price already sits inside both the historical and DCF valuation ranges despite the distorted TWI-based implied downside.
The valuation gap is unusually large: HRMY's current price of $37.26 versus an implied price of $3.82 implies -89.8% downside under the P/S-based framework. However, HRMY's current price is already within its historical band and DCF range, suggesting TWI-based implied price is likely distorted by TWI's weaker fundamentals rather than reflecting HRMY's intrinsic value.
Supporting Metrics
